share_log

There's Been No Shortage Of Growth Recently For Pediatrix Medical Group's (NYSE:MD) Returns On Capital

There's Been No Shortage Of Growth Recently For Pediatrix Medical Group's (NYSE:MD) Returns On Capital

最近Pediatrix Medical Group(紐交所代碼:MD)的資本回報增長沒有短缺。
Simply Wall St ·  2024/12/10 11:20

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. Speaking of which, we noticed some great changes in Pediatrix Medical Group's (NYSE:MD) returns on capital, so let's have a look.

如果您不確定尋找下一個翻倍投資的起點,可以留意幾個關鍵趨勢。理想情況下,一個業務應該展現出兩個趨勢;首先是資本回報率(ROCE)的增長,其次是投入資本的增加。簡單來說,這類型的企業是在進行復利運作,意味着它們持續在更高的收益率下再投資其收益。說到這一點,我們注意到Pediatrix Medical Group(紐交所:MD)的資本回報率發生了一些很好的變化,我們來看一下。

What Is Return On Capital Employed (ROCE)?

什麼是資本回報率(ROCE)?

Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on Pediatrix Medical Group is:

爲了澄清,如果您不確定,ROCE是評估公司在其業務中投資的資本所賺取的稅前收入(以百分比表示)的指標。對於Pediatrix Medical Group,這個計算的公式是:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

資本利用率 = 利息和稅前利潤(EBIT) ÷ (總資產 - 流動負債)

0.097 = US$165m ÷ (US$2.1b - US$373m) (Based on the trailing twelve months to September 2024).

0.097 = 16500萬美元 ÷ (21億 - 373百萬)(基於截至2024年9月的過去十二個月)。

Therefore, Pediatrix Medical Group has an ROCE of 9.7%. Even though it's in line with the industry average of 10%, it's still a low return by itself.

因此,Pediatrix Medical Group的ROCE爲9.7%。儘管這與行業平均水平10%相當,但單獨來看仍然是一個較低的回報。

big
NYSE:MD Return on Capital Employed December 10th 2024
紐交所:MD 使用的資本回報率 2024年12月10日

In the above chart we have measured Pediatrix Medical Group's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Pediatrix Medical Group for free.

在上面的圖表中,我們測量了Pediatrix Medical Group之前的資本回報率(ROCE)與其之前的表現,但未來無疑更加重要。如果您願意,您可以免費查看覆蓋Pediatrix Medical Group的分析師的預測。

What The Trend Of ROCE Can Tell Us

ROCE的趨勢可以告訴我們什麼

Pediatrix Medical Group has not disappointed in regards to ROCE growth. The data shows that returns on capital have increased by 36% over the trailing five years. The company is now earning US$0.1 per dollar of capital employed. Interestingly, the business may be becoming more efficient because it's applying 55% less capital than it was five years ago. If this trend continues, the business might be getting more efficient but it's shrinking in terms of total assets.

在資本回報率(ROCE)增長方面,Pediatrix Medical Group並沒有讓人失望。數據表明,資本回報在過去五年中增長了36%。該公司現在每投入1美元資本就能賺取0.1美元。有趣的是,公司的效率可能在提高,因爲現在所用的資本比五年前少55%。如果這種趨勢持續下去,業務可能變得更加高效,但總資產卻在減少。

What We Can Learn From Pediatrix Medical Group's ROCE

我們可以從Pediatrix Medical Group的ROCE中學到什麼

From what we've seen above, Pediatrix Medical Group has managed to increase it's returns on capital all the while reducing it's capital base. Astute investors may have an opportunity here because the stock has declined 48% in the last five years. With that in mind, we believe the promising trends warrant this stock for further investigation.

從我們看到的情況來看,Pediatrix Medical Group成功地在減少資本基礎的同時提高了資本回報率。精明的投資者可能在這裏有機會,因爲這隻股票在過去五年中下跌了48%。考慮到這一點,我們相信這些有希望的趨勢值得進一步調查。

On a separate note, we've found 3 warning signs for Pediatrix Medical Group you'll probably want to know about.

另外,我們發現了Pediatrix Medical Group的3個警告信號,您可能會想要了解。

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

對於喜歡投資於穩健公司的投資者,可以查看這個免費的穩健資產負債表和高股本回報率公司的列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論